NDF Report, page-9

wouldn't it be nice


What happens after the arbitration concludes? With the Mylan license still in place and not abrogated by the
outcome of any arbitration, there is potential to negotiate continued development of the product with Mylan. The
commercial opportunity of the daptomycin product is strong. Cubicin® was a >US$1bn best seller for Merck just
prior to the loss of US market exclusivity, and a new formulation called Cubicin® RF, which is stable at room
temperature and only requires sterile water to reconstitute, has helped maintain the franchise at US$382m in 2017 sales. More broadly, the daptomycin reformulation will have shown the power of TPM® to reformulate large
market injectable drugs and with antibiotic drug development now coming back into favour globally thanks to
concerns about drug-resistant microbes, there will be other injectables to work on in this space.  The global market
for injectable antibiotics has been estimated at ~US$9bn39.